GSK raises full-year profit forecast
GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines. The London-listed drugmaker said it now expects a...
Stay updated with breaking news from Eva Mathews. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines. The London-listed drugmaker said it now expects a...
The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth. On
(Reuters) - Consumer healthcare company Haleon's first-quarter revenue missed market estimates on Wednesday, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a surge last year. Revenues stood at 2....
(Reuters) -GSK raised its full-year profit forecast on Wednesday on strong demand for vaccines and specialty medicines though it noted sales growth would slow in the second half. CEO Emma Walmsley's strategy has focussed on vaccines and infectious diseases and a shift in its HIV focus to long-acting treatment and prevention therapies. It expects 2024 sales to grow in the upper end of its 5% to 7% forecast range.
Consumer healthcare company Haleon's first-quarter revenue missed market estimates on Wednesday, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a...